VPA mediates bidirectional regulation of cell cycle progression through the PPP2R2A-Chk1 signaling axis in response to HU

Benyu Su, David Lim, Chenyang Qi, Zhongwei Zhang, Junxiao Wang, Fengmei Zhang, Chao Dong, Zhihui Feng

Research output: Contribution to journalArticlepeer-review

19 Downloads (Pure)

Abstract

Cell cycle checkpoint kinases play a pivotal role in protecting against replicative stress. In this study, valproic acid (VPA), a histone deacetylase inhibitor (HDACi), was found to promote breast cancer MCF-7 cells to traverse into G2/M phase for catastrophic injury by promoting PPP2R2A (the B-regulatory subunit of Phosphatase PP2A) to facilitate the dephosphorylation of Chk1 at Ser317 and Ser345. By contrast, VPA protected normal 16HBE cells from HU toxicity through decreasing PPP2R2A expression and increasing Chk1 phosphorylation. The effect of VPA on PPP2R2A was at the post-transcription level through HDAC1/2. The in vitro results were affirmed in vivo. Patients with lower PPP2R2A expression and higher pChk1 expression showed significantly worse survival. PPP2R2A D197 and N181 are essential for PPP2R2A-Chk1 signaling and VPA-mediated bidirectional effect on augmenting HU-induced tumor cell death and protecting normal cells.

Original languageEnglish
Article number114
Number of pages16
JournalCell death & disease
Volume14
DOIs
Publication statusPublished - 13 Feb 2023

Keywords

  • cell cycle
  • VPA
  • HDAC inhibitors
  • PPP2R2A-Chk1
  • Phosphatase
  • HU
  • N181

Fingerprint

Dive into the research topics of 'VPA mediates bidirectional regulation of cell cycle progression through the PPP2R2A-Chk1 signaling axis in response to HU'. Together they form a unique fingerprint.

Cite this